JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
130 hedge funds and large institutions have $243M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 65 increasing their positions, 24 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
130
Holders Change
+6
Holders Change %
+4.84%
% of All Funds
2.27%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
20
Increased
65
Reduced
24
Closed
14
Calls
$340K
Puts
$1.73M
Net Calls
-$1.39M
Net Calls Change
+$1.24M
Top Buyers
| 1 |
1
Assenagon Asset Management
Senningerberg,
Luxembourg
|
$4.64M |
| 2 |
2
BlackRock
New York
|
$16.7M |
| 3 |
CS
3
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
$2.29M |
| 4 |
O
4
OrbiMed
New York
|
$14.6M |
| 5 |
5
Millennium Management
New York
|
$3.12M |
